CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 207 enrolled
Drug / intervention
Demcizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02289898
NCT02289898Phase 2Completed
CompareCT.gov

A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

OncoMed Pharmaceuticals, Inc.·interventional·Posted Nov 13, 2014·Updated Sep 28, 2020

In Brief

A Phase 2 clinical trial evaluating Demcizumab, Abraxane®, and 2 other interventions for Pancreatic Cancer. Completed, enrolled 207 participants across 42 sites in 6 countries.

Detailed Summary

This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesAustralia, Belgium, Canada, Spain, United Kingdom, United States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 13, 2014
Enrollment StartApr 20, 2015
Primary CompletionMay 1, 2017
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.6 years ago

Interventions

Demcizumabdrug

administered intravenously

Abraxane®drug

administered intravenously

gemcitabinedrug

administered intravenously

Placebodrug